Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-15-001759
Filing Date
2015-03-13
Accepted
2015-03-13 17:06:32
Documents
6
Effectiveness Date
2015-03-13

Document Format Files

Seq Description Document Type Size
1 DEFA14A a2015proxystatement.htm DEFA14A 630882
2 ajbackgroundpicture.jpg GRAPHIC 10605
3 cumberlandlogoa02a01.jpg GRAPHIC 12534
4 cumberlandpharmalogoa01.jpg GRAPHIC 37721
5 untitleda01a01.jpg GRAPHIC 9167
6 xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-15-001759.txt   732318
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: DEFA14A | Act: 34 | File No.: 001-33637 | Film No.: 15700170
SIC: 2834 Pharmaceutical Preparations